Hormone replacement therapy (HRT) is frequently prescribed to healthy women to ameliorate menopausal symptoms. HRT is used long term (≥ 1 year) to prevent chronic disease in older women. The objective of this study was to review the benefits and risks of HRT and studies of menopause or HRT in Taiwan via a MEDLINE search. Recommendations are provided for future HRT research in Taiwan. Randomized, double-blind, placebo-controlled clinical trials are considered the gold standard of scientific evidence. A MEDLINE literature search (January 1966-July 2002) identified 23 papers on trials (≥ 1 year) that met the inclusion criteria. The results showed that various HRT regimens used for more than 1 year caused more harm than good in healthy menopausal women and that there was no benefit for women with coronary artery disease, Alzheimer's disease, hysterectomy, hysterosalpingooophorectomy, and ischemic stroke. None of this research was conducted in Taiwan. A MEDLINE search using the key words "estrogen replacement therapy and menopause in Taiwan" identified 16 studies. There was only one, short-term, HRT trial. No evidence suggested benefits from long-term HRT in menopausal women in Taiwan. Hormone replacement therapy (HRT) is frequently prescribed to healthy women as a preventative measure. Short-term (< 1 year) HRT use to ameliorate menopausal symptoms has been reported [1] . Healthy women also take long-term HRT with the purpose of preserving their health and to prevent disease [2] .
The number of studies relating to menopause have increased in the past decade in Taiwan. However, the response of the medical profession in Taiwan, primarily that of gynecologists, to the results of the WHI trial has generally been defensive, with continued insistence on the effectiveness of HRT. Medical professionals argued in the media that the absolute excess risks per 10,000 person-years in the WHI trial were too low to cause concern (Liberty Times 2002/7/13), and because the trial used one drug regimen only, it is doubtful whether the results can be applied to other lower dosages of these drugs or other formulations (United Daily News 2002/7/12; Liberty Times 2002/7/14).
The objective of this study was to provide evidence gathered from HRT research conducted outside Taiwan and to offer recommendations for future HRT research directions in Taiwan. Randomized, double-blind, placebo-controlled trials are considered the most comprehensive methods of investigating the effectiveness of a drug in most epidemiologic or public health studies. The approval of a drug for clinical use by the US Food and Drug Administration (FDA) largely depends on the results of these trials [4] . Thus, the authors selected randomized, double-blind, placebocontrolled HRT trials (≥ 1 year duration) through a MEDLINE search and reviewed the benefits and risks of HRT use in menopausal women.
METHOD
Data sources were selected from studies with Englishlanguage abstracts identified by a computerized MEDLINE search (January 1966-July 2002) using the key words estrogen replacement therapy, doubleblind, clinical trials, and random allocation. Only longterm trials, in which participants had been randomized to at least 1 year of therapy, were included.
RESULTS
Twenty-three papers on long-term (≥1 year) clinical trials from important journals of medicine and menopause met the inclusion criteria ( Table 1 ). The samples were selected from healthy women and women with hysterectomy, hysterosalpingooophorectomy, coronary artery disease, Alzheimer's disease, or ischemic stroke. Most trials were conducted in the USA [3, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , with the remainder in Holland [21, 22] , Denmark [23, 24] , Australia [25] , and Italy [26] ; there were none conducted in Taiwan. Only 16 studies conducted in Taiwan, with English-language abstracts, were identified in a similar MEDLINE search using the key words estrogen replacement therapy and menopause [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] (Table 2) . Randomized, double-blind, placebo-controlled trials (≥ 1 year)
Of the 23 studies, nine were part of long-term trials (3-13 years) [3, [5] [6] [7] [8] [9] [10] 14, 15] and 13 were multicenter studies [3, [5] [6] [7] [8] [9] [10] [14] [15] [16] [17] [18] 20] .
For healthy women using estrogen (CEE 1.25, 0.625, 0.45, or 0.3 mg) or estrogen plus progesterone (CEE 0.625, 0.45, or 0.3 mg plus MPA 10, 2.5, or 1.5 mg), six papers reported that risks exceeded benefits and five reported benefits only (Table 3) .
The risks of long-term estrogen or estrogen plus progesterone therapy (5.2 or 3 years) in healthy menopausal women were: an increase in coronary heart disease, stroke, pulmonary embolism, breast cancer [3] , and mean triglyceride levels [8] and enhanced development of endometrial hyperplasia [9] . The benefits of long-term HRT use (1 to 5.2 years) in healthy menopausal women were: a decrease in the risk of colorectal cancer and hip fracture [3] , an increase in bone mineral density [7, 10, 12] , bone mineral content [10] , and postcranial and oral bone mass [11] , a slowing of bone loss [14] , and decreases in the mean concentration of low-density lipoprotein cholesterol [6, 8] and the risk of forgetfulness [5] .
Benefits of long-term HRT use (3 years) in women with coronary artery disease were found in women with flushing, but there were risks in women without flushing [14] . Women with flushing who were assigned to HRT had improved mental health and fewer depressive symptoms during follow-up compared with those assigned to placebo. Women without flushing who were assigned to HRT had greater declines in physical function and energy/fatigue during follow-up (Table 4) .
Among women with coronary artery disease, Alzheimer's disease and hysterectomy, three trials reported that long-term HRT (1 to 4 years) had no benefit in slowing the progression of Alzheimer's disease [15] , in global cognitive or functional outcomes [15] , and in the reduction of the overall rate of coronary heart disease [16, 17] (Table 4) .
Some trials with other HRT regimens were conducted in Europe as the particular hormone replacement combination investigated in the WHI is not available there (Table 5) .
Among healthy women using various HRT regimens for 2 years, benefits were found with continuous norethindrone acetate-ethinyl estradiol (NA-EE2) combinations, 17 beta-estradiol, sequential estradiol/ norethisterone acetate (E2/NETA) combinations, and continuous E2/NETA or E2/cyproterone acetate combinations: increased bone mineral density [18] , bone loss prevention [19] , and climacteric symptom relief [23, 24] . No benefit was found with tibolone [22] .
When women with hysterectomy, hysterosalpingooophorectomy, and ischemic stroke or transient ischemic attack used raloxifene, 17 beta-estradiol, and transdermal estradiol (1 to 2.8 years), no benefit was found in the systolic function of the left ventricle [21] , in reducing the recurrence of stroke [20] , and in modifying atrioventricular conduction and ventricular repolarization [26] .
HRT and menopause research in Taiwan
We found 16 studies reporting on HRT and the menopause in Taiwan (Tables 6 and 7 ). They covered: the perception of menopausal women toward menopause [27, 37] ; the risk of osteoporosis [29] , high- * Women with flushing who were assigned to HRT had improved mental health and fewer depressive symptoms over follow-up compared with those assigned to placebo. Women without flushing who were assigned to HRT had greater declines in physical function and energy/ fatigue over follow-up. CAD = coronary artery disease; AD = Alzheimer's disease; CHD = coronary heart disease. density lipoprotein cholesterol concentrations [31] , and breast cancer factors [35, 36, 38] in menopausal women; increases in total cholesterol, low-density lipoprotein cholesterol, triglycerides, apoprotein B [28, 32] and body fat [33, 34] ; age at menopause [30, 40] and menopausal symptoms [30, 39, 41] ; and the effectiveness of estrogen treatment for menopausal women [42] . Only one study was a short-term HRT trial [42] . Most of the studies were conducted in Taipei [28, [30] [31] [32] 35, 36, [38] [39] [40] [41] [42] . The studies included questionnaire surveys, case-control studies, clinical studies, interviewbased studies, cross-sectional studies, and cohort studies [28, 32] . No evidence suggested long-term benefits from HRT among menopausal women in Taiwan. We found no randomized, double-blind, placebocontrolled HRT trial (≥ 1 year) conducted in Taiwan. Only one short-term HRT trial was published [42] , and there was no evidence to suggest long-term benefits from HRT use.
Main results

Risks exceed benefits
T h e t r i a l s r e v i e w e d i n t h i s p a p e r w e r e predominantly conducted in the USA and Europe; none were conducted in Asia. Therefore, research into the special coping strategies of menopausal women in Asia is essential. Eighty-two studies with Englishlanguage abstracts were selected from a computerized MEDLINE search using the key words estrogen replacement therapy and menopause in various Asian countries ( Table 2 ). The main themes reported were: the occurrence of climacteric complaints or menopausal symptoms and menopausal age [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] ; the effects of HRT treatment or compliance and the sale of estrogen replacement products [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] ; the perception of menopause, depression, psychological distress, and the effects of counseling on climacteric symptoms [69] [70] [71] [72] ; the risk of Alzheimer's disease, menopause-related v a s c u l a r c h a n g e s , b o n e l o s s , b o n e d e n s i t y , contraceptive status and sexual function ; the pattern of postmenopausal bleeding, the measurement of normal ovaries and plasma lipid and lipoprotein levels [103] [104] [105] ; and special diets [106] [107] [108] .
These Asian studies do not provide any additional credible scientific evidence to that from the 23 reports on randomized, double-blind, placebo-controlled HRT trials conducted in the USA and Europe.
RECOMMENDATIONS
Three major propositions are recommended for future research in Taiwan. First, the purpose of healthy women taking long-term HRT is to preserve health and prevent disease [2] . Freedman et al argue that a single outcome is often not an appropriate paradigm for trials of disease prevention but the interventions often have potential effects on several diseases [109] . Thus, a major rationale for a trial may be to estimate all of these effects more precisely, thereby providing a basis for informed public health decisions [109] . Simply repeating the WHI trial or other similar HRT research with subjects in Taiwan is undesirable. It is more appropriate to investigate the effects of HRT on a wider range of diseases or disciplines. For instance, breast cancer in Taiwan occurs in younger women compared with the West. The question is whether the increase in HRT use will cause a rise in the incidence of breast cancer in Taiwan. This issue will require further research. A multidisciplinary research team composed o f m e d i c a l e x p e r t s , p u b l i c h e a l t h e x p e r t s , epidemiologists, and statisticians to carry out this research would be optimal. Furthermore, the experience of menopausal women, their health needs and medical demands, and long-term follow-up of women's health are essential in Taiwan.
Second, the NIH in the USA, responding to the demand of women's organizations and congresswomen in 1991, initiated a large-scale estrogenprogestin versus placebo trial in healthy menopausal women [110] . However, there was little reaction from the National Health Research Institutes in Taiwan when the WHI study in the USA was stopped. Although the Department of Health in Taiwan has posted guidelines for HRT use on its website in response to the halted WHI study, they do not provide information on healthcare for menopausal women and alternatives when women do not want to use medication. In Taiwan, HRT resources offered to medical personnel and to the media are distributed predominantly by the pharmaceutical industry. To combat this, we propose that the National Health Research Institutes in Taiwan take responsibility for making HRT resources available. With respect to the health of the general public, there is a need for ethical management and responsibility from related medical societies in combating the overmarketing of medicines in the Taiwanese media. Additional research is needed to tackle this situation.
Third, regarding the use of HRT, gynecologists' or allied physicians' arguments over the different physical constitutions of women in the East and West have been increasing in Taiwan since the WHI trial was stopped. Instead of singling out HRT use, research attention should be focused on the effect of any type of medication on different physical constitutions. This kind of research is recommended to begin as soon as possible in order to avoid any possible overdosage side effects.
